Literature DB >> 8764084

Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase.

J Goudsmit1, A De Ronde, D D Ho, A S Perelson.   

Abstract

We monitored a subject newly infected with a zidovudine-resistant human immunodeficiency virus type 1 strain and found that in the absence of drug, the viral population with the resistance-conferring tyrosine (TAC) codon 215 of reverse transcriptase was gradually replaced. By using standard formulas to model the effects of selection at a single locus in an asexual haploid population, the relative fitness gain of the viral population with a single mutation at codon 215 creating a serine (TCC) was calculated. We concluded that a viral population with a serine at reverse transcriptase codon 215 conferring zidovudine sensitivity was between 0.4 and 2.3% more fit.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8764084      PMCID: PMC190530     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  13 in total

1.  Quantitation of relative fitness and great adaptability of clonal populations of RNA viruses.

Authors:  J J Holland; J C de la Torre; D K Clarke; E Duarte
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

Review 2.  Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.

Authors:  B A Larder
Journal:  J Gen Virol       Date:  1994-05       Impact factor: 3.891

3.  Exponential increases of RNA virus fitness during large population transmissions.

Authors:  I S Novella; E A Duarte; S F Elena; A Moya; E Domingo; J J Holland
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

4.  First case of new infection with zidovudine-resistant HIV-1 among prospectively studied intravenous drug users and homosexual men in Amsterdam, The Netherlands.

Authors:  A de Ronde; R Schuurman; J Goudsmit; A van den Hoek; C Boucher
Journal:  AIDS       Date:  1996-02       Impact factor: 4.177

5.  HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.

Authors:  A S Perelson; A U Neumann; M Markowitz; J M Leonard; D D Ho
Journal:  Science       Date:  1996-03-15       Impact factor: 47.728

6.  Sensitive procedure for the amplification of HIV-1 RNA using a combined reverse-transcription and amplification reaction.

Authors:  M Nijhuis; C A Boucher; R Schuurman
Journal:  Biotechniques       Date:  1995-08       Impact factor: 1.993

7.  A microtitre format point mutation assay: application to the detection of drug resistance in human immunodeficiency virus type-1 infected patients treated with zidovudine.

Authors:  S Kaye; C Loveday; R S Tedder
Journal:  J Med Virol       Date:  1992-08       Impact factor: 2.327

8.  Syncytium-inducing (SI) phenotype suppression at seroconversion after intramuscular inoculation of a non-syncytium-inducing/SI phenotypically mixed human immunodeficiency virus population.

Authors:  M Cornelissen; G Mulder-Kampinga; J Veenstra; F Zorgdrager; C Kuiken; S Hartman; J Dekker; L van der Hoek; C Sol; R Coutinho
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

9.  Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy.

Authors:  I Nájera; A Holguín; M E Quiñones-Mateu; M A Muñoz-Fernández; R Nájera; C López-Galíndez; E Domingo
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

10.  Viral dynamics in human immunodeficiency virus type 1 infection.

Authors:  X Wei; S K Ghosh; M E Taylor; V A Johnson; E A Emini; P Deutsch; J D Lifson; S Bonhoeffer; M A Nowak; B H Hahn
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

View more
  48 in total

1.  Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val.

Authors:  P L Sharma; C S Crumpacker
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

Review 2.  A fossil record of zidovudine resistance in transmitted isolates of HIV-1.

Authors:  D R Kuritzkes
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

3.  Procedures for reliable estimation of viral fitness from time-series data.

Authors:  Sebastian Bonhoeffer; Andrew D Barbour; Rob J De Boer
Journal:  Proc Biol Sci       Date:  2002-09-22       Impact factor: 5.349

4.  Fluorescent dye terminator sequencing methods for quantitative determination of replication fitness of human immunodeficiency virus type 1 containing the codon 74 and 184 mutations in reverse transcriptase.

Authors:  Viktoria Nurpeisov; Selwyn J Hurwitz; Prem L Sharma
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

5.  A human immunodeficiency virus type 1-infected individual with low viral load harbors a virus variant that exhibits an in vitro RNA dimerization defect.

Authors:  Hendrik Huthoff; Atze T Das; Monique Vink; Bep Klaver; Fokla Zorgdrager; Marion Cornelissen; Ben Berkhout
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

6.  A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Authors:  Robert W Shafer; Kathryn Dupnik; Mark A Winters; Susan H Eshleman
Journal:  HIV Seq Compend       Date:  2001

7.  Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation.

Authors:  P L Sharma; C S Crumpacker
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

Review 8.  HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance.

Authors:  Robert W Shafer; Soo-Yon Rhee; Deenan Pillay; Veronica Miller; Paul Sandstrom; Jonathan M Schapiro; Daniel R Kuritzkes; Diane Bennett
Journal:  AIDS       Date:  2007-01-11       Impact factor: 4.177

9.  The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions.

Authors:  Mian-er Cong; Walid Heneine; J Gerardo García-Lerma
Journal:  J Virol       Date:  2006-12-27       Impact factor: 5.103

10.  Design requirements for interfering particles to maintain coadaptive stability with HIV-1.

Authors:  Igor M Rouzine; Leor S Weinberger
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.